作者
Richard D Kennedy, Max Bylesjo, Peter Kerr, Timothy Davison, Julie M Black, Elaine W Kay, Robert J Holt, Vitali Proutski, Miika Ahdesmaki, Vadim Farztdinov, Nicolas Goffard, Peter Hey, Fionnuala McDyer, Karl Mulligan, Julie Mussen, Eamonn O'Brien, Gavin Oliver, Steven M Walker, Jude M Mulligan, Claire Wilson, Andreas Winter, Diarmuid O'Donoghue, Hugh Mulcahy, Jacintha O'Sullivan, Kieran Sheahan, John Hyland, Rajiv Dhir, Oliver F Bathe, Ola Winqvist, Upender Manne, Chandrakumar Shanmugam, Sridhar Ramaswamy, Eduardo J Leon, William I Smith Jr, Ultan McDermott, Richard H Wilson, Daniel Longley, John Marshall, Robert Cummins, Daniel J Sargent, Patrick G Johnston, D Paul Harkin
发表日期
2011/12/10
期刊
Journal of Clinical Oncology
卷号
29
期号
35
页码范围
4620-4626
出版商
American Society of Clinical Oncology
简介
Purpose
Current prognostic factors are poor at identifying patients at risk of disease recurrence after surgery for stage II colon cancer. Here we describe a DNA microarray–based prognostic assay using clinically relevant formalin-fixed paraffin-embedded (FFPE) samples.
Patients and Methods
A gene signature was developed from a balanced set of 73 patients with recurrent disease (high risk) and 142 patients with no recurrence (low risk) within 5 years of surgery.
Results
The 634–probe set signature identified high-risk patients with a hazard ratio (HR) of 2.62 (P < .001) during cross validation of the training set. In an independent validation set of 144 samples, the signature identified high-risk patients with an HR of 2.53 (P < .001) for recurrence and an HR of 2.21 (P = .0084) for cancer-related death. Additionally, the signature was shown to perform independently from known prognostic factors (P < .001 …
引用总数
学术搜索中的文章
RD Kennedy, M Bylesjo, P Kerr, T Davison, JM Black… - Journal of Clinical Oncology, 2011